Q Xu1, J R Casey2, A Almudevar3, M E Pichichero4. 1. Rochester General Hospital Research Institute, Rochester, NY, USA. 2. Legacy Pediatrics, Rochester, NY, USA. 3. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA. 4. Rochester General Hospital Research Institute, Rochester, NY, USA; Legacy Pediatrics, Rochester, NY, USA. Electronic address: michael.pichichero@rochesterregional.org.
Abstract
OBJECTIVES: We previously found that nasopharyngeal (NP) colonization by Streptococcus pneumoniae elicits mucosal antibody responses to three protein vaccine candidates: pneumococcal histidine triad protein D (PhtD), pneumococcal choline-binding protein A (PcpA), and detoxified pneumolysin (PlyD1). Here we sought to determine if mucosal antibody levels to the proteins correlated with protection from acute otitis media (AOM) and NP colonization. METHODS: A total of 228 NP samples were prospectively collected from 100 healthy infants at 6-24 months of age. Whenever children were diagnosed with AOM, middle ear fluids were collected to confirm the diagnosis by microbiological culture. NP mucosal IgG and IgA were quantified by ELISA. RESULTS: Higher NP mucosal antibody levels to S. pneumoniae proteins correlated with significantly decreased likelihood of developing AOM caused by S. pneumoniae during 3 to 12 months of subsequent prospective monitoring. Specifically, children who did not experience AOM (n=111samples) caused by S. pneumoniae had two- to five-fold higher mucosal IgG levels to PcpA (all p values <0.01), six- to eight-fold higher IgA to PhtD (all p values <0.05); two- to three-folder higher IgA to PcpA (all p values <0.05), and two- to three-fold higher IgA to PlyD1 (p 0.08, p 0.03 and p 0.08) compared with children who did experience AOM (n=18samples). No association between mucosal antibody levels to the three proteins and NP colonization with S. pneumoniae was found. CONCLUSION: Higher NP mucosal IgG levels to PcpA, and IgA to PhtD, PcpA and PlyD1 correlate with reduced risk of development of S. pneumoniae AOM infection but not with reduced risk of NP colonization in young children.
OBJECTIVES: We previously found that nasopharyngeal (NP) colonization by Streptococcus pneumoniae elicits mucosal antibody responses to three protein vaccine candidates: pneumococcal histidine triad protein D (PhtD), pneumococcal choline-binding protein A (PcpA), and detoxified pneumolysin (PlyD1). Here we sought to determine if mucosal antibody levels to the proteins correlated with protection from acute otitis media (AOM) and NP colonization. METHODS: A total of 228 NP samples were prospectively collected from 100 healthy infants at 6-24 months of age. Whenever children were diagnosed with AOM, middle ear fluids were collected to confirm the diagnosis by microbiological culture. NP mucosal IgG and IgA were quantified by ELISA. RESULTS: Higher NP mucosal antibody levels to S. pneumoniae proteins correlated with significantly decreased likelihood of developing AOM caused by S. pneumoniae during 3 to 12 months of subsequent prospective monitoring. Specifically, children who did not experience AOM (n=111samples) caused by S. pneumoniae had two- to five-fold higher mucosal IgG levels to PcpA (all p values <0.01), six- to eight-fold higher IgA to PhtD (all p values <0.05); two- to three-folder higher IgA to PcpA (all p values <0.05), and two- to three-fold higher IgA to PlyD1 (p 0.08, p 0.03 and p 0.08) compared with children who did experience AOM (n=18samples). No association between mucosal antibody levels to the three proteins and NP colonization with S. pneumoniae was found. CONCLUSION: Higher NP mucosal IgG levels to PcpA, and IgA to PhtD, PcpA and PlyD1 correlate with reduced risk of development of S. pneumoniae AOM infection but not with reduced risk of NP colonization in young children.
Authors: Ankie Lebon; Nelianne J Verkaik; Joost A M Labout; Corné P de Vogel; Herbert Hooijkaas; Henri A Verbrugh; Willem J B van Wamel; Vincent W V Jaddoe; Albert Hofman; Peter W M Hermans; Jiangtao Ma; Tim J Mitchell; Henriette A Moll; Alex van Belkum Journal: Infect Immun Date: 2011-01-31 Impact factor: 3.441
Authors: Michael J Binks; Allen C Cheng; Heidi Smith-Vaughan; Theo Sloots; Michael Nissen; David Whiley; Joseph McDonnell; Amanda J Leach Journal: BMC Infect Dis Date: 2011-06-07 Impact factor: 3.090
Authors: Sabine M P J Prevaes; Willem J B van Wamel; Corné P de Vogel; Reinier H Veenhoven; Elske J M van Gils; Alex van Belkum; Elisabeth A M Sanders; Debby Bogaert Journal: Infect Immun Date: 2012-03-26 Impact factor: 3.441
Authors: Michael E Pichichero; Ravinder Kaur; Janet R Casey; Qingfu Xu; Anthony Almudevar; Martina Ochs Journal: Hum Vaccin Immunother Date: 2012-04-12 Impact factor: 3.452
Authors: Birgit Simell; Petra Ahokas; Mika Lahdenkari; Jan Poolman; Isabelle Henckaerts; Terhi M Kilpi; Helena Käyhty Journal: Vaccine Date: 2009-06-12 Impact factor: 3.641
Authors: Alison S Laufer; Joshua P Metlay; Janneane F Gent; Kristopher P Fennie; Yong Kong; Melinda M Pettigrew Journal: mBio Date: 2011-02-01 Impact factor: 7.867
Authors: Debby Bogaert; Bart Keijser; Susan Huse; John Rossen; Reinier Veenhoven; Elske van Gils; Jacob Bruin; Roy Montijn; Marc Bonten; Elisabeth Sanders Journal: PLoS One Date: 2011-02-28 Impact factor: 3.240
Authors: Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham Journal: Int J Pediatr Otorhinolaryngol Date: 2019-12-18 Impact factor: 1.675
Authors: Els van Westen; Martien C M Poelen; Germie P J M van den Dobbelsteen; Eliud O Oloo; Martina M Ochs; Nynke Y Rots; Cecile A C M van Els Journal: PLoS One Date: 2018-03-06 Impact factor: 3.240